TNGX earnings date and last-quarter result: last quarter beat, P/E -33.86. Updated 2026-07-23.
Tango Therapeutics (TNGX) Research Hub
Tango Therapeutics (TNGX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 22.2 USD (-4.88%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -33.86, market cap 3.55B. This hub links to the full technical, earnings and options research available for TNGX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 22.2 USD (-4.88%) |
| 52-week range | 20.98 USD – 34.39 USD |
| Trend regime | Range |
| 14-day RSI | 50.9 (Neutral) |
| Trailing P/E | -33.86 |
| Market cap | 3.55B |
| Dividend yield | 0.00% |
Available research for TNGX
Covered Call on TNGX: how it works, illustrative setup around the real 22.2 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on TNGX: how it works, illustrative setup around the real 22.2 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on TNGX: how it works, illustrative setup around the real 22.2 USD price, max profit/loss, breakeven and when to use it. Educational.
TNGX technical analysis: range, last 22.2 USD, RSI 50.9, 52w range 20.98 USD–34.39 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is TNGX in?
Tango Therapeutics (TNGX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is TNGX in an uptrend or downtrend?
As of 2026-10-26, TNGX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is TNGX's trailing P/E ratio?
TNGX's trailing P/E is -33.86, with a market cap of 3.55B. See the earnings research page for full valuation detail.